OLR1, also known as LOX-1, was first characterized decades ago as an endothelial receptor that binds oxidized low-density lipoprotein, the modified cholesterol particles implicated in atherosclerosis. In the years since its discovery, accumulating evidence has linked the receptor to cancer biology in multiple tumor types, where it has been associated with poor outcomes, immune suppression, and the behavior of myeloid-derived suppressor cells. Until now, however, its precise contribution to gastric cancer and, crucially, its influence on the tumor microenvironment remained poorly defined. The new study was designed to close that gap by combining large-scale clinical data analysis with laboratory experiments probing both the function and the mechanism of OLR1 in gastric cancer cells.

To establish the clinical relevance of the receptor, the team mined The Cancer Genome Atlas, a comprehensive public repository of genomic and clinical data from cancer patients. Their analysis revealed that OLR1 is significantly upregulated in gastric cancer tissue compared with healthy tissue, and that elevated expression correlates with unfavorable prognosis. In practical terms, patients whose tumors expressed high levels of the receptor tended to fare worse, suggesting that OLR1 is not merely a passenger alteration but a biologically meaningful marker of aggressive disease. The researchers then validated these findings experimentally in gastric cancer cell lines, confirming that the patterns observed in patient data are reflected in the molecular behavior of the tumor cells themselves.

With the correlation established, the investigators turned to gain- and loss-of-function experiments to determine whether OLR1 actively drives malignancy or merely accompanies it. When they forced gastric cancer cells to overproduce the receptor, the cells became more prolific: proliferation and migration both increased, and tumors grew faster in animal models. Conversely, when OLR1 was silenced or knocked down, these malignant behaviors were curtailed. These complementary approaches, conducted both in vitro and in vivo, provide strong evidence that OLR1 is a functional driver of gastric cancer progression rather than a passive biomarker. The in vivo assays were conducted under protocols approved by the Committee of Experimental Animal Ethics of Nanjing Medical University, and the findings together paint a coherent picture of a receptor that empowers tumor cells to divide, move, and expand.

The most consequential part of the study, however, lies in its mechanistic findings. Cancer rarely advances through tumor cell autonomy alone; it depends heavily on co-opting the surrounding microenvironment, a complex ecosystem of immune cells, stromal cells, blood vessels, and signaling molecules. Within this ecosystem, macrophages occupy a pivotal position. These innate immune cells are remarkably plastic, capable of adopting radically different functional states. The M1 phenotype is generally inflammatory and antitumoral, while the M2 phenotype is immunosuppressive, wound-healing oriented, and, in the context of cancer, protumorigenic. Tumors rich in M2-polarized macrophages tend to suppress cytotoxic T cell activity, remodel tissue architecture to favor invasion, and resist immunotherapy.

Using a series of mechanistic assays, Chen, Wang, and colleagues demonstrated that OLR1 promotes the polarization of macrophages toward this immunosuppressive M2 phenotype. In other words, gastric cancer cells carrying high levels of the receptor do not merely grow faster on their own; they actively recruit and reprogram the immune cells around them to become allies of the tumor. This reprogramming contributes to a protumorigenic microenvironment in which the normal immune surveillance that might otherwise eliminate malignant cells is blunted. The finding aligns with a growing body of literature showing that tumor-associated macrophages are among the most important non-malignant players in cancer progression and that lipid metabolism and lipid-sensing receptors can shape macrophage behavior.

The second mechanistic pillar of the study concerns a signaling pathway familiar to almost every cancer biologist: nuclear factor kappa B, or NF-κB. This transcription factor family governs inflammation, cell survival, and immune responses, and its chronic activation is a hallmark of many tumors, including those of the gastrointestinal tract. The researchers found that OLR1 activates NF-κB signaling in gastric cancer cells, and that this activation underlies the tumor-promoting behaviors they observed. The connection is biologically plausible: prior work has shown that LOX-1 engagement can trigger NF-κB-dependent inflammatory signaling in other cell types, including microglial cells under hypoxic conditions, and NF-κB is well established as a regulator of cytokine production and immune modulation within the tumor microenvironment. By tying OLR1 to NF-κB activation in gastric cancer, the study links a lipid-sensing receptor to one of the central inflammatory engines of malignancy.

The convergence of these two mechanisms, NF-κB activation within tumor cells and M2 macrophage polarization within the microenvironment, offers a compelling explanation for why high OLR1 expression portends poor outcomes. A tumor that simultaneously accelerates its own growth and dismantles the immune response against it gains a decisive survival advantage. Importantly, the authors propose that OLR1 could serve not only as a prognostic biomarker, helping clinicians identify patients at higher risk of aggressive disease, but also as a therapeutic target. If OLR1 activity can be pharmacologically blocked, the dual benefits of restraining tumor cell proliferation and restoring a more favorable immune contexture might be achievable. Anti-LOX-1 strategies have already been explored in the cardiovascular field, where the receptor is a recognized player in atherosclerotic disease, providing a potential pharmacological starting point for oncology applications.

The study also situates itself within a broader and rapidly evolving research landscape. Recent work has implicated a variety of tumor-derived signals, including complement components such as C4BPA acting through the C5a-C5aR1-STAT3 axis, the cytokine subunit INHBA acting through PI3K/AKT signaling, and exosomal microRNAs, in driving M2 macrophage polarization in gastric cancer. Metabolic reprogramming, particularly of lipid metabolism, has emerged as a recurring theme in how tumors shape macrophage behavior, and OLR1’s identity as a receptor for oxidized lipids fits squarely within this framework. The findings may also help explain why gastric cancer frequently resists immunotherapy: tumors can deploy multiple, redundant mechanisms to polarize macrophages toward a suppressive state, and effective interventions may need to target these pathways in combination.

Supported by funding from the Changzhou Science and Technology Bureau and Nanjing Medical University, the research represents a step toward precision oncology for gastric cancer, a disease in which the identification of clinically actionable biomarkers remains an urgent unmet need. As with any preclinical study, translation to the clinic will require additional validation, including studies of OLR1 blockade in robust animal models and, ultimately, clinical trials. Nevertheless, by demonstrating that a single receptor can simultaneously fuel tumor-intrinsic aggressiveness through NF-κB and orchestrate immune evasion through macrophage polarization, the work provides a mechanistically grounded rationale for pursuing OLR1 as both a marker of poor prognosis and a point of therapeutic attack. For a cancer that remains a leading cause of cancer-related mortality worldwide, such dual-purpose targets are precisely the kind of molecular leverage points that the field has been searching for.

Subject of Research: The role of the OLR1 receptor in gastric cancer progression via NF-κB activation and M2 macrophage polarization

Article Title: OLR1 drives gastric cancer progression through NF-κB activation and immunosuppressive macrophage polarization

Article References: Chen, Z., Wang, Y., Xu, X., Zhao, M., & Zhou, X. (2026). OLR1 drives gastric cancer progression through NF-κB activation and immunosuppressive macrophage polarization. Medical Oncology, 43(10), Article 275. https://doi.org/10.1007/s12032-026-03394-4

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03394-4

Keywords: OLR1, gastric cancer, NF-κB signaling, macrophage polarization, tumor microenvironment, M2 macrophages, biomarker, immunosuppression, cancer progression, Medical Oncology, drives, gastric

The finding lands at the intersection of two of the most rapidly evolving fields in cancer biology: the tumor microbiome and the study of fungi as overlooked members of our resident microbial communities. For decades, research into the microbiome concentrated overwhelmingly on bacteria, and rightly so, given their staggering abundance. But fungi, though numerically minor, possess qualities that make them uniquely capable of influencing their hosts. They have robust cell walls built from beta-glucans and other sugar polymers, they can switch between morphological forms, and they are armed with molecules that interact directly with the innate immune system. In recent years, fungal DNA and even intact fungal cells have been detected inside tumors ranging from pancreatic cancer to melanoma, prompting an urgent question: are these organisms contaminants, opportunists exploiting a weakened tissue, or drivers of malignant progression?

The new study, led by Lai and colleagues, adds substantial weight to the third possibility, at least in the context of advanced prostate cancer. By analyzing fecal samples and tumor tissue from patients with castration-resistant prostate cancer, the team found that Nakaseomyces glabratus was enriched in both compartments relative to comparisons, indicating that the fungus is not only more abundant in the gut of these patients but also physically present within the tumor microenvironment itself. That dual enrichment is important. A microbe found solely in stool could simply reflect a systemic shift in body ecology; a microbe found inside the tumor, in the same patients, raises the possibility of migration — that organisms originating in the intestinal lumen can translocate across epithelial barriers, travel through circulation or adjacent tissues, and colonize tumor sites.

Nakaseomyces glabratus, known in older literature as Candida glabrata, is no exotic pathogen. It is a genuine commensal, carried harmlessly by a large fraction of healthy people on mucosal surfaces of the gut, the genitourinary tract, and elsewhere. In immunocompromised individuals, however, it can become an opportunistic pathogen and is a recognized cause of invasive candidiasis in hospital settings. Its evolutionary kinship with Candida albicans makes the new findings particularly thought-provoking, because C. albicans has already been implicated in other contexts in which commensal fungi appear to reshape host physiology, from inflammatory bowel disease to oral carcinogenesis. The new work extends this emerging paradigm to the prostate, an organ whose tumor microenvironment had not previously been considered a destination for migrating fungi.

The castrated mouse experiments provide the study’s most consequential evidence. Prostate cancers typically depend on androgen receptor signaling, which is why androgen deprivation therapy — surgical or chemical castration — is a mainstay of treatment for advanced disease. Over time, however, tumors adapt and progress despite near-castrate hormone levels, becoming the castration-resistant form that accounts for most prostate cancer deaths. When the researchers gave Nakaseomyces glabratus to castrated mice bearing prostate tumors, the fungus accelerated cancer progression in this precisely defined hormonal context. In other words, the organism’s pro-tumor effect was observed under the very conditions that define the lethal, treatment-resistant stage of human disease, closely mirroring the patient population in which the fungus was found to be enriched.

How might a commensal yeast push a tumor toward faster growth? The authors’ demonstration does not yet fully resolve the mechanism, but the broader literature offers several plausible avenues. Fungal cell wall components, including beta-glucans and mannans, are recognized by innate immune receptors such as Dectin-1 and Toll-like receptors, which can trigger inflammatory programs that tumors frequently exploit for growth, survival, and immune evasion. Chronic low-grade inflammation within the tumor microenvironment can promote angiogenesis, remodel the extracellular matrix, and suppress effective anti-tumor immunity, all of which favor progression. Fungi can also alter the local metabolic landscape, consume nutrients, and engage in cross-kingdom interactions with bacteria that themselves modulate inflammation and therapy response. Disentangling which of these pathways Nakaseomyces glabratus activates in the prostate will be a central task for follow-up research.

The translocation question is equally compelling. The intestinal barrier is a heavily policed boundary, and yet a growing body of work shows that microbial migration from gut to distant tissues is far more common than once believed. Bacterial species have been traced from the gut lumen into pancreatic tumors, breast tumors, and lymph nodes, sometimes with measurable functional consequences for disease course. The new study suggests fungi can join this list. If Nakaseomyces glabratus indeed migrates from the gut into prostate tumors, the clinical implications are immediately apparent: the gut mycobiome becomes a potential modifiable risk factor, and strategies to reduce fungal load, alter fungal community composition, or block fungal recognition pathways could, in principle, slow disease progression in affected patients.

Caution is, as always in this field, warranted. Enrichment and acceleration in mice establish association and a causal effect in an animal model, but they do not by themselves prove that the fungus drives progression in every patient, nor that eradicating it would improve outcomes in humans. Tumor-associated microbes can be difficult to distinguish from contaminants, and the field has grappled with reproducibility concerns surrounding low-biomass microbiome sequencing. Moreover, host factors — immune status, diet, prior antifungal or antibiotic exposure, and disease stage — likely shape whether a commensal yeast remains benign or becomes pro-tumorigenic. The most rigorous next steps will include longitudinal studies tracking fungal burden as disease progresses, mechanistic dissection of the immune signaling involved, and intervention experiments in models that test whether reducing the fungus reverses the accelerated growth.

Nevertheless, the conceptual shift is hard to overstate. Prostate cancer research has concentrated on hormones, genetics, and immune checkpoints; the possibility that a common commensal fungus physically resides inside prostate tumors and shapes their trajectory adds an entirely new layer to the disease model. It also resonates with an expanding appreciation that the human body is a multi-kingdom ecosystem, in which fungi, bacteria, viruses, and host cells engage in a continuous negotiation whose outcome can be health or disease. If further work confirms and extends these findings, mycobiome profiling could one day sit alongside PSA testing and genomic analysis in the clinical workup of advanced prostate cancer, and antifungal or microbiome-targeted interventions could emerge as adjuncts to existing therapies.

For now, the study stands as a vivid reminder that the microbes we carry with us every day are not always neutral companions. A yeast that spends most of its existence quietly metabolizing in our intestines can, under the right circumstances, find its way into a tumor and help it grow faster. Understanding when, how, and in whom that happens may open one of the most unexpected new fronts in the fight against castration-resistant prostate cancer — a front that begins not in the prostate at all, but in the gut.

Subject of Research: Enrichment of the commensal fungus Nakaseomyces glabratus in castration-resistant prostate cancer and its acceleration of tumor progression in mice

Article Title: Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression

Article References: Lai, P., Liu, L., Pernigoni, N., Du, Y., Braga, D., Troiani, M., Attanasio, G., Li, Y., Song, P., Pasquini, E., Rezzonico Jost, T., Huang, X., Maddalena, M., Mosole, S., Rinaldi, A., Pecoraro, G., Pedrani, M., Valdata, A., Bancaro, N., … Alimonti, A. (2026). Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression. Nature Cancer. https://doi.org/10.1038/s43018-026-01229-9

Image Credits: AI Generated

DOI: 10.1038/s43018-026-01229-9

Keywords: Nakaseomyces glabratus, prostate cancer, castration-resistant prostate cancer, tumor microbiome, mycobiome, fungal translocation, commensal fungi, tumor microenvironment, androgen deprivation, cancer progression, Nature Cancer, Commensal